(Q36481002)

14 August 2017

1 reference

title

Molecular biology of epidermal growth factor receptor inhibition for cancer therapy (English)

1 reference

14 August 2017

0 references

Sabrina Oliveira

1

1 reference

ORCID Public Data File 2021

author name string

Paul M P van Bergen en Henegouwen

series ordinal

2

1 reference

14 August 2017

Gert Storm

series ordinal

3

1 reference

14 August 2017

Raymond M Schiffelers

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Expert Opinion on Biological Therapy

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

6

1 reference

14 August 2017

605-617

1 reference

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Active and inactive conformations of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Clathrin-independent endocytosis of ubiquitinated cargos

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Mechanisms controlling EGF receptor endocytosis and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Why the epidermal growth factor receptor? The rationale for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Targeting the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Recent developments related to the EGFR as a target for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Current status of cetuximab for the treatment of patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Epidermal growth factor receptor inhibition strategies in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Review of epidermal growth factor receptor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Clinical experience with gefitinib: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Argos inhibits epidermal growth factor receptor signalling by ligand sequestration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

21 January 2018

Cell cycle and no end.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Gefitinib ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Pharmacological background of EGFR targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

Mismatch repair gene expression and genetic instability in testicular germ cell tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.6.605

21 January 2018

Identifiers

DOI

10.1517/14712598.6.6.605

1 reference

14 August 2017

1 reference